All Oncology News

Ruben A. Mesa, MD, discusses the significance of the RESPONSE study for patients with polycythemia vera.

Jia Ruan, MD, PhD, discusses the pivotal analysis of the combination of lenalidomide plus rituximab, as well as the next steps for this regimen in the field of mantle cell lymphoma.

Daniel DeRemer, PharmD, assistant director of Clinical Therapeutics and Incubator, discusses patient education on oral chemotherapy.

Dan Klein, President and CEO of Patient Access Network Foundation, discusses payment assistance for patients with cancer.

David H. Ilson, MD, PhD, discusses practice-changing trials, the optimal available therapies, and how immunotherapy fits into the future treatment paradigm for gastric cancer.

John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.

David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.

Jesper B. Andersen, MSc, PhD, discusses the findings of a study evaluating a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma.

Michael Broderson, PharmD, Nebraska Cancer Specialists, discusses the management of patients with cancer.

Karen Kellogg, PharmD, Cardinal Health, discusses the important role that the oncologist plays in dispensing.

The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Christopher Crane, MD, discusses modern innovative techniques in GI cancers.

Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.

Eileen O’Reilly, MD, discusses novel therapeutic approaches for the treatment of patients with pancreatic cancer.

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Neal Dave, PharmD, Texas Oncology, discusses the role of positive quality interventions (PQI).

Aleix Prat, MD, PhD, discusses the novel treatments being developed in the paradigm of HER2-positive breast cancer.

Randy Burkholder, vice president, Policy & Research, PhRMA, discusses the role that providers play in policy reform.

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System.

Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.

An analysis of the phase III OlympiAD study showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Nancy E. Kemeny, MD, discusses the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic colorectal cancer.

Diane Reidy-Lagunes, MD, discusses ongoing developments for the treatment of patients with gastrointestinal and pancreatic NETs.

The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

The FDA has granted a breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia.

Nearly 7 in 10 patients with locally advanced or metastatic BRAF V600E–mutated anaplastic thyroid cancer responded to treatment with the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).